Dexamethasone in Experimental Haemophilus Meningitis Xavier Saez-Llorens, Hamid S

Total Page:16

File Type:pdf, Size:1020Kb

Dexamethasone in Experimental Haemophilus Meningitis Xavier Saez-Llorens, Hamid S Enhanced Attenuation of Meningeal Inflammation and Brain Edema by Concomitant Administration of Anti-CD18 Monoclonal Antibodies and Dexamethasone in Experimental Haemophilus Meningitis Xavier Saez-Llorens, Hamid S. Jafari, Carlos Severien, Francisco Parras, Kurt D. Olsen, Eric J. Hansen, Irwin 1. Singer,* and George H. McCracken, Jr. Departments of Pediatrics and Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9063; and *Department ofBiochemical and Molecular Pathology, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065 Abstract Elevated concentrations of proinflammatory substances such as TNF and IL-1 trigger initiation of the inflammatory Antiinflammatory therapy has been shown to reduce the ad- process and provoke profound pathophysiological changes that verse pathophysiological consequences that occur in bacterial result in alteration of cerebrospinal fluid (CSF)l hydrodynam- meningitis and to improve outcome from disease. In the present ics and in activation of the metabolic and coagulation path- study, modulation of two principal steps of the meningeal in- ways (7-9). Dexamethasone has been shown to inhibit produc- flammatory cascade was accomplished by concomitant adminis- tion of these cytokines at transcriptional and translational lev- tration of dexamethasone to diminish overproduction of cyto- els, especially when given before liberation of active bacterial kines in response to a bacterial stimulus and of a monoclonal components into the subarachnoid space (10, 1 1). antibody directed against adhesion-promoting receptors on leu- Influx of leukocytes into CSF can further amplify these kocytes to inhibit recruitment of white blood cells into the sub- pathophysiologic events because their accumulation contrib- arachnoid space. Dexamethasone and antibody therapy pro- utes to a sluggish CSF circulation and decreased resorption, duced a marked attenuation of all indices of meningeal inflam- and because of liberation of cytotoxic products on degranula- mation and reduction of brain water accumulation after H. tion (12). Before entering the subarachnoid space leukocytes influenzae-induced meningitis in rabbits compared with results must adhere to brain endothelial cells presumably through a of each agent given alone and of untreated animals. In addition, family of adhesion-promoting receptors and ligands located on the enhanced host's meningeal inflammatory reaction that fol- leukocyte cell membranes and endothelium that have been pre- lows antibiotic-induced bacterial lysis was profoundly amelior- viously activated by exposure to cytokines (13, 14). Treatment ated when dual therapy was administered without affecting of experimental lapine meningitis induced by intracisternal in- clearance rates of bacteria from cerebrospinal fluid and vascu- oculation of living bacteria (e.g., S. pneumoniae, H. influenzae, lar compartments. The combination of both therapeutic ap- N. meningitidis), their cell wall components (e.g., teichoic proaches may offer a promising mode of treatment to improve acid, lipopolysaccharide), or by human cytokines with mono- further the outcome from bacterial meningitis. (J. Clin. Invest. clonal antibodies (MAbs) directed against the CDl 1/CD 1 8 leu- 1991. 88:2003-2011.) Key words: anti-CD18 antibodies - dexa- kocyte adhesion receptors was shown to decrease transendoth- methasone * experimental meningitis elial passage of polymorphonuclear cells into CSF and to re- duce significantly indices of meningeal inflammation (6, 15). Introduction The use of anti-CD18 MAbs has also been shown to inhibit Antiinflammatory therapy of animals and humans with bacte- polymorphonuclear leukocyte accumulation and plasma leak- rial meningitis has been shown to decrease meningeal inflam- age in rabbits with experimentally-induced inflammatory skin mation, blood-brain barrier permeability, intracranial hyper- lesions (16) and to reduce multiple organ injury and death tension, brain edema, tissue damage, long-term neurological caused by increased leukocyte adhesiveness in an experimental sequelae, and mortality rates associated with this disease (1, 2). model of generalized ischemia-reperfusion injury (17). Likewise, the transient enhancement of the host's inflamma- The aim of this study was to assess whether the combina- tory response that commonly follows initiation of antibiotic tion of dexamethasone (DXM) and anti-CD 1 1/CD 18 antibod- treatment has been significantly attenuated when agents have ies would be more effective than either agent alone in prevent- been used that selectively interfere with production of inflam- ing or attenuating the pathophysiologic events that occur in matory mediators (e.g., dexamethasone, cyclooxygenase inhibi- experimental meningitis induced by H. influenzae type b or its tors) or with influx of leukocytes into the subarachnoid space purified lipooligosaccharide (LOS). (e.g., pentoxifylline, anti-CD 1 8 receptor antibodies) (3-6). Methods Address correspondence to George H. McCracken, Jr., M.D., Dept. of Pediatrics, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Preparation ofHib endotoxin Dallas, TX 75235-9063. Hib endotoxin (LOS) was purified from cells of Hib strain DL42 by Receivedfor publication 16 January 1991 and in revisedform 29 using the hot phenol-water method of Westphal and Jann (18), as July 1991. modified by Johnson and Perry (19). The purity of this LOS prepara- tion was confirmed by SDS-PAGE, followed by silver staining (20) and J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/91/12/2003/09 $2.00 1. Abbreviations used in this paper: CSF, cerebrospinal fluid; DXM, Volume 88, December 1991, 2003-2011 dexamethasone; LOS, lipooligosaccharide. Treatment ofExperimental Meningitis with Anti-CD18 Antibodies and Dexamethasone 2003 Western blot analysis using hyperimmune rat serum to Hib DL42 (21). ELISA assays were conducted to measure the plasma concentration 20 ng of the endotoxin, which is contained in 2 X 106 bacterial cells, of IB4 or OKM-l MAbs. Immulon-2 (Dynatech Laboratories, Inc., was chosen as the inoculum to induce meningitis because this amount Alexandria, VA) 96-well plates were coated with affinity-purified rab- has consistently induced meningeal inflammation in this rabbit model bit anti-mouse IgG2a (Zymed Labs Inc., San Francisco, CA) for detec- (22) and because CSF samples from patients with Hib meningitis con- tion of IB4, or affinity-purified rabbit anti-mouse IgG2b (Zymed Labs) tain from 104 to I0' CFU/ml. for detection of OKM- 1. These trapping antibodies were dissolved at 5 ,ug/ml in 0.1 M NaHCO3 for 1 h at 250C. After this and all subsequent Bacterial strain steps, washing was performed with PBS using a ProPette automated Hib strain DL42 is a non-fl-lactamase-producing strain isolated from plate washer (Cetus Corp., Emeryville, CA). Samples of rabbit plasma the CSF of a child with meningitis. This strain is fully virulent in the containing unknown amounts of IB4 or OKM- 1 were diluted in PBS infant rat model for Hib invasive disease and belongs to LOS antigenic containing 0.05% Tween-20 and 0.1% BSA and added to the wells; group 2, which is the predominant LOS antigenic type among invasive 100-,gl aliquots were incubated for 1 h at 370C in triplicate. Standard Hib isolates (23). The minimum inhibitory concentration of ceftriax- calibration curves were constructed using purified IB4 or OKM-I at one for this Hib strain was 0.01 fIg/ml. concentrations ranging from 10 to 400 ng/ml. After washing, bound A final inoculum of - 1 x 106 colonies/ml taken from a culture IB4 or OKM-I were detected with a 1:500 dilution (in PBS containing which contained bacteria in a log phase of growth was prepared. Ani- 1% BSA) of alkaline phosphatase-conjugated affinity-purified rabbit mals were then intracisternally inoculated with 0.2 ml of this bacterial anti-mouse IgG2a (Zymed Labs) for IB4 and anti-mouse IgG2b for suspension. detection of OKM-1. After incubation for 1 h at 370C and further washing, the quantities of bound conjugate were detected by incubat- Experimental meningitis model ing all wells with a 1 mg/ml solution ofp-nitrophenyl phosphate in 0.1 This study was approved by the Institutional Review Board for Animal M 2,2 amino-methyl-propanediol buffer (pH 10.3, Zymed Labs) for 30 Research of The University of Texas Southwestern Medical Center at min at 250C. The absorbance of each well was determined at 405 nm Dallas. with a UV Max ELISA plate reader (Molecular Devices, Inc., Menlo The rabbit model of experimental meningitis, originally described Park, CA), and the plasma concentrations of IB4 or OKM-I calculated by Dacey and Sande (24), was used in a modified form. New Zealand using the accompanying software (Molecular Devices, Inc.). White male rabbits (2-3 kg) were anesthetized with intramuscular in- jections of ketamine (40 mg/kg) and acepromazine (3 mg/kg) and Study design placed in a stereotactic frame. A spinal needle was introduced into the Three different sets of experiments were conducted: (a) Hib LOS-in- cisterna magna and 0.2 ml ofCSF withdrawn. Animals were then inoc- duced meningitis. (b) Hib-live organism-induced meningitis without ulated with same volume of either Hib LOS or live Hib organisms. antibiotic treatment. (c) Hib-live organism-induced meningitis with Subsequent CSF samples (0.2-0.3 ml) were obtained at different times antibiotic treatment. according to study design. Immediately after collection, the CSF ali- Experiment 1. 36 rabbits received
Recommended publications
  • Supplementary Appendix
    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
    [Show full text]
  • Philippine Clinical Practice Guidelines on the Diagnosis And
    Pediatric Infectious Diseases Society of the Philippines Journal Vol 16 No.2 pp 2-42 Jul-Dec 2015 PIDSP and CNSP Bacterial Meningitis TWG, Acute Bacterial Meningitis CPG 2015 PHILIPPINE CLINICAL PRACTICE GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE BACTERIAL MENINGITIS IN INFANTS AND CHILDREN Copyright 2015 A joint project of the Pediatric Infectious Disease Society of the Philippines (PIDSP) and Child Neurology Society of the Philippines (CNSP) 2 Pediatric Infectious Diseases Society of the Philippines Journal Vol 16 No.2 pp.2-42 Jul-Dec 2015 PIDSP and CNSP Bacterial Meningitis TWG, Acute Bacterial Meningitis CPG 2015 TABLE OF CONTENTS Page I. Introduction A. History of the guideline 5 B. Target users of the guideline 5 C. Forming the guideline 5 D. PIDSP/CNSP Steering Committee 6 E. Criteria for Assessment of Strength of Evidence and Recommendation 6 II. Recommendations A. Diagnosis of Acute Bacterial Meningitis 1. What are the signs and symptoms to suspect acute bacterial meningitis? 7 2. What is the definitive test for bacterial meningitis? 8 3. How do we differentiate acute bacterial meningitis from other CNS infections? 9 4. What are the contraindications to lumbar puncture? 9 5. What are the ancillary tests in the diagnosis of bacterial m eningitis? What is the value of each diagnostic test? a. Complete blo od count (CBC) 10 b. Blood culture 11 c. C-reactive protein (CRP) 11 d. Polymerase chain reaction (PCR) 13 e. Latex Agglutination Test (LAT) 13 f. Procalcitonin 14 6. What is the role of imaging tests in the diagnosis of bacterial meningitis? 15 B.
    [Show full text]
  • General Medical Microbiology and Infectious Disease BMS 6301
    General Medical David L. Balkwill, Ph.D., Course Microbiology Director and Infectious Disease [email protected] BMS 6301 (850) 644-9219 2004 – 2005 Course Syllabus x Click here for the schedule Description: This course provides learning opportunities in the basic principles of medical microbiology and infectious disease. It covers mechanisms of infectious disease transmission, principles of aseptic practice, and the role of the human body’s normal microflora. The biology of bacterial, viral, fungal, and parasitic pathogens and the diseases they cause are covered. Relevant clinical examples are provided. The course provides the conceptual basis for understanding pathogenic microorganisms and the mechanisms by which they cause disease in the human body. It also provides opportunities to develop informatics and diagnostic skills, including the use and interpretation of laboratory tests in the diagnosis of infectious diseases. Format: Combination of 1-hour lecture/case-based class sessions and 2-hour case-based discussion/demo lab sessions with small groups (see topical syllabus, below). Course Director: David L. Balkwill, Ph.D. Office: Room 526 Office Hours: Open – students are welcome to stop by anytime. Phone: 644-9219 [email protected] Other Instructors: Lecture: Myra Hurt, Ph.D. Small Group Facilitation: Curtis Altmann, Ph.D., Susanne Cappendijk, Ph.D., Trent Clarke, Ph.D., Edward Klatt, M.D., Graham Patrick, Ph.D., and Yanchang Wang, Ph.D. Required Text: Medical Microbiology, 4th Ed. (2002) Murray, Rosenthal, Kobayashi, and Pfaller, Mosby-Year Book, ISBN: 0323012132. Recommended Texts: Mechanisms of Microbial Disease, 3rd Ed. (1998) Schaechter, Engelberg, Eisenstein, and Medoff, Lippincott, ISBN: 0683076051.
    [Show full text]
  • February 1, 2008 May 1, 2010 ABSCESS Staphyloccus Aureus
    Winnipeg Regional Health Authority Infection Prevention & Control Manual Clinical Presentation, Type of Infective Material Route of Incubation Period of Duration of Comments Microorganism, Infectious Precautions Transmission Communicability Precautions Disease ABSCESS Minor: Pus Direct & indirect Variable Duration of drainage Duration of Minor: Drainage is contained by Staphyloccus aureus Routine contact drainage dressing. Group A Streptococcus Major: Drainage not contained by Major: Other bacteria dressing. Contact ACQUIRED IMMUNE DEFICIENCY Routine Blood, body fluids Mucosal or Weeks to From onset of For life Follow the WRHA Post Exposure SYNDROME containing visible percutaneous years infection Blood & Body Fluid Post Exposure AIDS, ARC, or HIV blood, CSF, pleural exposure to Protocol Management Policy. Report an exposure to infective Antibody Positive, peritoneal, infective pericardial, amniotic material material e.g., needle-stick or blood Suspected Human fluids, semen, & Breastmilk spill/splash immediately to the Immunodeficiency vaginal secretions ingestion Occupational Health Department. Virus (HIV) Infection Refer to Specific Disease Protocol: AIDS/HIV. ACTINOMYCOSIS Routine Not person to Normal flora: infection usually Actinomyces species person secondary to trauma. ADENOVIRUS Routine Eye drainage Direct & indirect 2-14 days Until symptoms Duration of Different strains can be responsible for Conjunctivitis Children <6 yrs: contact cease illness respiratory and gastrointestinal disease. Contact Minimize exposure of immunocompromised
    [Show full text]
  • Author Section
    AUTHOR SECTION patients with new onset of fever, demographic, clinical, and laborato- Mycoplasma spp. Overall, the spectrum of antibacterial activity indi- ry variables were obtained during the 2 days after inclusion, while cates a potential role for this combination in the treatment of diffi- microbiological results for a follow-up period of 7 days were collect- cult-to-treat Gram-positive infections, including those caused by ed. Patients were followed up for survival or death, up to a maximum multidrug-resistant organisms. Since this activity extends to Gram- of 28 days after inclusion. MEASUREMENTS AND RESULTS: Of negative respiratory bacteria, quinupristin/dalfopristin may also find all patients, 95% had SIRS, 44% had sepsis with a microbiologically a role in the treatment of atypical, as well as typical, pneumonia. confirmed infection, and 9% died. A model with a set of variables all significantly (p<0.01) contributing to the prediction of mortality was Boubaker A. et al. [Investigation of the urinary tract in children in nuclear med- derived.The set included the presence of hospital-acquired fever, the icine]. Rev Med Suisse Romande. 2000; 120(3) : 251-7.p Abstract: peak respiratory rate, the nadir score on the Glasgow coma scale, and The early detection of urologic abnormalities by antenatal sonogra- the nadir albumin plasma level within the first 2 days after inclusion. phy has resulted in the investigation of many infants and neonates for This set of variables predicted mortality for febrile patients with suspicion of either obstructive uropathy or reflux nephropathy. microbiologically confirmed infection even better.The predictive val- Nuclear medicine techniques allow to assess renal parenchyma ues for mortality of SIRS and sepsis were less than that of our set of integrity, to detect pyelonephritic scars and to measure absolute and variables.
    [Show full text]
  • Meningitis Protocol
    Winnipeg Regional Health Authority Acute Care Infection Prevention & Control Manual MENINGITIS PROTOCOL Meningitis is an inflammation of the meninges, the thin lining that surrounds the brain and spinal cord. It can be caused by many bacteria and viruses. Viral infections are the most common cause of meningitis; bacterial infections are the second most common cause. Other rarer causes of meningitis include fungi, parasites, and non-infectious causes, including those related to drugs. Severity of illness and treatment for meningitis differ depending on the cause. It is therefore important to know the specific cause of meningitis: bacterial meningitis is usually more severe than viral, fungal, or parasitic meningitis. Implement Droplet Precautions for all suspect meningitis types until a type has been confirmed/diagnosis determined. Not all cases of meningitis require Additional Precautions. Pediatric: • Implement Droplet/Contact Precautions until etiology determined. • If confirmed as bacterial in origin, implement Droplet Precautions. • If confirmed as viral in origin, implement Contact Precautions for children who are incontinent or unable to comply with hygiene practice. Adult: implement Droplet Precautions until Neisseria meningitidis ruled out. Type of Type of Meningitis Duration of Precautions Precautions Etiology unknown – adult Droplet Until etiology is determined Etiology unknown – pediatric Droplet/Contact Haemophilus influenzae Routine Practices Ongoing type B – adult Haemophilus influenzae Until 24 hours after Droplet type
    [Show full text]
  • Reportable Disease Desk Reference
    Page 1 REPORTABLE DISEASE DESK REFERENCE Division of Epidemiology and Health Planning Department for Public Health Commonwealth of Kentucky April, 2006 Page 2 FOREWORD In the United States, requirements for reporting diseases are mandated by state laws or regulations, and the list of reportable diseases in each state varies. The Kentucky Disease Surveillance Administrative Regulations 902 KAR 2:020 require reporting of Communicable Diseases to the local health departments and the Kentucky Department for Public Health. Additionally, state health departments report cases of selected diseases to the Centers for Disease Control and Prevention (CDC) National Notifiable Disease Surveillance System (NNDSS), on a weekly basis. These data are published weekly in the Morbidity Mortality Weekly Report (MMWR). An updated final report is published annually in the Summary of Notifiable Diseases. With the 2006 version of the desk reference, we have tried to adhere as closely as possible to the case definitions developed by the CDC and the Council of State and Territorial Epidemiologists (CSTE) published in “Case Definitions for Public Health Surveillance”, MMWR 1997; 46:RR-10 and available on the CDC’s Epidemiology Program Office website, http://www.cdc.gov/epo/dphsi/casedef/index.htm. As uniform case definitions are adopted by the states, the incidence of reported diseases in different geographic areas may be more meaningfully compared at the local, state, and national levels. KYEPHRS AND THE DISEASE SURVEILLANCE MODULE The Kentucky Electronic Public Health Record System (KY-EPHRS) provides the backbone of an integrated electronic health record, including disease surveillance. The Disease Surveillance is one of several modules that make up KY-EPHRS.
    [Show full text]
  • Haemophilus Influenzae Type B (Hib) Meningitis in the Pre-Vaccine Era: a Global Review of Incidence, Age Distributions, and Case-Fatality Rates
    WHO/V&B/02.18 ORIGINAL: ENGLISH Vaccines and Biologicals Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates World Health Organization WHO WHO/V&B/02.18 ORIGINAL: ENGLISH Vaccines and Biologicals Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates John V. Bennett, Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA Alexander E. Platonov, Head, Laboratory of Meningococcal Infection and Bacterial Meningitis, Central Institute of Epidemiology, Moscow, Russian Federation Mary P. E. Slack, Head, WHO Collaborating Centre on Haemophilus influenzae, Public Health Laboratory Service Haemophilus Reference Unit, Oxford, United Kingdom Peter Mala, Anthony H. Burton and Susan E. Robertson, Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland World Health Organization WHO The Department of Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible. This document was produced by the Vaccine Assessment and Monitoring team of the Department of Vaccines and Biologicals Ordering code: WHO/V&B/02.18 Printed: October 2002 This document is available on the Internet at: www.who.int/vaccines-documents/ Copies may be requested from: World Health Organization Department of Vaccines and Biologicals CH-1211 Geneva 27, Switzerland • Fax: + 41 22 791 4227 • Email: [email protected] • © World Health Organization 2002 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]).
    [Show full text]
  • Meningitis, Encephalitis and Neonatal Sepsis 1 GBD 2017 1 WHO
    The global burden of meningitis in children: Challenges with interpreting global health estimates Supplementary Appendix Contents Mortality modelling methods – Meningitis, encephalitis and neonatal sepsis 1 GBD 2017 1 WHO-MCEE 2000-2017 3 Pathogen specific meningitis mortality and incidence modelling methods 4 GBD 2017 4 MCEE/JHSPH 5 Tables and Figures Table S1: ICD10 codes mapped to meningitis, encephalitis and neonatal sepsis according to model 7 Table S2: Definitions of IHME’s GBD 2017 data quality star rating 12 Table S3: Location level covariates according to model 13 Table S4: Covariates used in WHO-MCEE’s multinomial logistic regression by age group, model and cause 14 Table S5: MCEE Final cause of death list 15 Table S6: MCEE modelled cause of death categories according to age 16 Figure S1: Quality of underlying cause of death data and modelling methods used to generate death estimates according to model. 17 Mortality modelling methods – Meningitis, encephalitis and neonatal sepsis This section provides a brief overview on how the different models derive meningitis, encephalitis and neonatal sepsis mortality estimates. However, full methodology is provided by the modellers elsewhere. Both GBD 2017 and MCEE 2000-2017 models used cause of death data from vital registration (VR) systems, sample registration systems (SR) and verbal autopsy (VA) studies to assign causes of death ensuring that the total number of deaths matches other estimates for the age-specific all-cause mortality. This involves the generation of data where data are The global burden of meningitis in children: Challenges with interpreting global health estimates Supplementary Appendix incomplete or completely missing.
    [Show full text]
  • Bacterial Meningitis Some Aspects of Diagnosis and Treatment GARRY HAMBLETON and PAMELA A
    Arch Dis Child: first published as 10.1136/adc.50.9.674 on 1 September 1975. Downloaded from Review article Archives of Disease in Childhood, 1975, 50, 674. Bacterial meningitis Some aspects of diagnosis and treatment GARRY HAMBLETON and PAMELA A. DAVIES From the Department of Paediatrics and Neonatal Medicine, Hammersmith Hospital, London Antimicrobial therapy has made few more drama- the male sex (Washburn, Medearis, and Childs, tic conquests than that of bacterial meningitis, 1965), congenital anomalies of or injury to the which it has transformed from the almost univer- central nervous system, and primary infection else- sally fatal illness of 30 years ago into one with a where, especially that adjacent to the meninges, are relatively low mortality. Yet the disease, which has other well established predisposing factors. Chil- its greatest impact in early childhood, poses a dren who have impaired defence mechanisms for a continuing threat and must be regarded as one of variety of reasons are a tiny minority but are never- the most challenging of medical emergencies. In the less being kept alive in increasing numbers for the United Kingdom and Eire in 1973, at least 109 much longer now, and are consequently in jeopardy. children under 15 years of age were reported to For instance, an association between pneumococcal have died from it (Public Health Laboratory Service, infection and sickle cell disease, a condition which 1974;) andinthe United States more thana quarter of may be associated with a defect in the properdin copyright. survivors from Haemophilus influenzae meningitis system (Johnston, Newman, and Struth, 1973) is alonehave beenfound tohave significantneurological well known, and Smith et al.
    [Show full text]
  • Meningococcal Disease: Always Consider in a Patient with Flu-Like Illness
    Meningococcal disease: Always consider in a patient with flu-like illness Patients with meningococcal disease can initially year (19.8 per 100 000 population), followed by children aged present with non-specific influenza-like symptoms. between one and four years (5.6 per 100 000 population).4 More specific signs and symptoms may develop There was a secondary peak in notification rate in young adults 4 as the illness progresses. Symptoms can rapidly aged 15–19 years (4.8 per 100 000 population). Among ethnic groups, the highest rate of meningococcal disease in 2012 progress from mild to life-threatening, therefore was in Māori (4.5 per 100 000 population), followed by Pacific suspected meningococcal disease is a medical peoples (3.7 per 100 000 population).4 This compares to a rate emergency. of 1.5 per 100 000 population in people of European or other ethnicity.4 Meningococcal disease is the term used to describe the two different types of illness caused by the bacterium Neisseria meningitidis: meningococcal meningitis and Identifying meningococcal disease in a patient with a meningococcal septicaemia.1 Meningococcal meningitis “flu-like” illness occurs when N. meningitidis multiplies on the meninges The first stage of meningococcal disease (prodromal stage) and in the cerebro-spinal fluid. Meningococcal septicaemia is associated with non-specific symptoms, which may persist occurs when N. meningitidis multiplies to pathogenic levels throughout the illness. These symptoms include acute fever, in the bloodstream.2 Septicaemia can occur in conjunction vomiting, nausea, lethargy, irritability, refusing food or drink, with meningitis, and is more likely to be fatal than meningitis headache, muscle and joint pain and respiratory symptoms.5 without septicaemia.3 Cough, particularly dry cough, is more indicative of influenza than meningococcal disease.6 There are at least 13 serotypes of N.
    [Show full text]
  • House Bill 420
    HOUSE BILL 420 Unofficial Copy 2001 Regular Session J1 1lr0076 ____________________________________________________________________________________ By: Chairman, Environmental Matters Committee (Departmental - Health and Mental Hygiene) Introduced and read first time: February 1, 2001 Assigned to: Environmental Matters _____________________________________________________________________________________ Committee Report: Favorable House action: Adopted Read second time: March 7, 2001 _____________________________________________________________________________________ CHAPTER_______ 1 AN ACT concerning 2 Reporting of Communicable Diseases 3 FOR the purpose of adding certain diseases to a list of diseases that are reportable by 4 a director of a medical laboratory to a certain health officer within a specified 5 period of time; modifying the existing designations of diseases on the list; 6 defining invasive disease; providing an exemption for a report of noncholera 7 vibriosis under certain circumstances; and generally relating to the reporting of 8 certain diseases by medical laboratories. 9 BY repealing and reenacting, with amendments, 10 Article - Health - General 11 Section 18-205 12 Annotated Code of Maryland 13 (2000 Replacement Volume) 14 (As enacted by Chapter 419 of the Acts of the General Assembly of 2000) 15 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF 16 MARYLAND, That the Laws of Maryland read as follows: 17 Article - Health - General 18 18-205. 19 (A) IN THIS SECTION, "INVASIVE DISEASE" MEANS A DISEASE IN WHICH AN 20 ORGANISM IS DETECTED IN A SPECIMEN TAKEN FROM A NORMALLY STERILE BODY 21 SITE. 2 HOUSE BILL 420 1 [(a) (1)] (B) The director of a medical laboratory shall submit a report to the 2 health officer for the county where the laboratory is located within 48 hours after an 3 examination of a specimen from a human body shows evidence of any of the following: 4 [(i) Gonorrhea.
    [Show full text]